Biodesix INC Form 4 insider transactions

Director Jean M. Franchi reports the settlement of restricted stock units into Biodesix Inc. common stock on April 1, 2025.

Charles M. Watts, a director at Bio-Rad Laboratories, exercised restricted stock units (RSUs) on March 31, 2025, acquiring 46,686 shares of common stock.

John Patience, Chairman and Director of Biodesix Inc., reports the vesting and acquisition of 46,686 common stock shares through restricted stock units on March 31, 2025.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., reports the acquisition of restricted stock units and stock options.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., reports the acquisition of stock options and restricted stock units.

Kieran O'Kane, Chief Commercial Officer of Biodesix Inc., reports acquisition of stock options and restricted stock units.

Biodesix CEO Scott Hutton reports the acquisition of restricted stock units and stock options, signaling changes in his beneficial ownership of the company's securities.

Robin Harper Cowie, CFO, Secretary, and Treasurer of Biodesix Inc., reports acquisition of stock options and restricted stock units on February 20, 2025.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., reports the vesting and sale of common stock to cover taxes, along with adjustments to restricted stock units.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., sold shares of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

Kieran O'Kane, Chief Commercial Officer of Biodesix Inc., reports the vesting and sale of restricted stock units to cover taxes, along with adjustments to his direct ownership of common stock.

Scott Hutton, President and CEO of Biodesix Inc., reports the sale of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

CFO Robin Harper Cowie reported the acquisition of 67,788 shares of common stock through the vesting of restricted stock units and the sale of 24,664 shares to cover taxes.

Director Jack Schuler of BioDeisx Inc. purchased 100,000 shares of common stock at a weighted average price of $1.2284 per share.

Director Lawrence T. Kennedy Jr. of Biodesix Inc. purchased 35,000 shares of common stock at a weighted average price of $1.1589 on November 21, 2024.

Director Jack Schuler of BioDeisx Inc. purchased 200,000 shares of common stock at an average price of $1.17.

BioDeisx's Chief Accounting Officer, Chris Vazquez, reported the acquisition of 602 shares through restricted stock units and the subsequent sale of 203 shares to cover taxes.

BioDeisx Chief Development Officer, Gary Pestano, sold shares to cover taxes after restricted stock units vested.

BioDeisx Chief Commercial Officer Kieran O'Kane reported the acquisition of 1,490 shares through restricted stock units and the sale of 462 shares to cover taxes.

BioDeisx CEO Scott Hutton sold shares to cover taxes after restricted stock units vested, while also acquiring shares through the vesting of those units.

BioDeisx CFO Robin Cowie sold shares to cover taxes after restricted stock units vested, while also acquiring shares through RSU vesting.

Biodesix Director Matthew Strobeck reports acquisition of common stock through multiple entities, with prices ranging from $1.38 to $1.405.

Director Jack Schuler reports purchasing 100,253 shares of Biodesix Inc. common stock at a weighted average price of $1.3624 on November 5, 2024, increasing his indirect holdings through the Jack W. Schuler Living Trust.

John Patience, Chairman at Biodesix, recently purchased 75,000 shares of the company's common stock at an average price of $1.3828 per share.

Director Hany Massarany recently purchased 22,500 shares of Bio-Rad Laboratories (BDSX) common stock at an average price of $1.3718 per share.

Director and 10% owner Lawrence T. Kennedy, Jr. reports purchasing additional shares of Biodesix Inc (BDSX) common stock.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., reports the acquisition and disposal of common stock and restricted stock units to cover taxes upon vesting.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., sold shares of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

Kieran O'Kane, Chief Commercial Officer of Biodesix Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover taxes.

Biodesix CEO Scott Hutton sold shares of common stock to cover taxes upon the vesting of restricted stock units (RSUs).